SSSamir N. Shah

Samir N. Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samir N. Shah has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure

    by Sanchit Sharma, Samagra Agarwal, Anoop Saraya, Ashok Kumar Choudhury, Sanjiv Saigal, A. S. Soin, Akash Shukla, Manoj K. Sahu, Laurentius A. Lesmana, Renaldi C. Lesmana, et al.

    Background and aims Early identification of non-response to steroids is critical in patients with autoimmune hepatitis (AIH) causing acute-on-chronic liver failure (ACLF). We assessed if this non-response can be accurately identified within first few days of treatment. Methods Patients with AIH-ACLF without baseline infection/hepatic encephalopathy were identified from APASL ACLF research consortium (AARC) database. Diagnosis of AIH-ACLF was based mainly on histology. Those treated with steroids were assessed for non-response (defined as death or liver transplant at 90 days for present study). Laboratory parameters, AARC, and model for end-stage liver disease (MELD) scores were assessed at baseline and day 3 to identify early non-response. Utility of dynamic SURFASA score [− 6.80 + 1.92*(D0-INR) + 1.94*(∆%3-INR) + 1.64*(∆%3-bilirubin)] was also evaluated. The performance of early predictors was compared with changes in MELD score at 2 weeks. Results Fifty-five out of one hundred and sixty-five patients (age—38.2 ± 15.0 years, 67.2% females) with AIH-ACLF [median MELD 24 (IQR: 22–27); median AARC score 7 (6–9)] given oral prednisolone 40 (20–40) mg per day were analyzed. The 90 day transplant-free survival in this cohort was 45.7% with worse outcomes in those with incident infections (56% vs 28.0%, p = 0.03). The AUROC of pre-therapy AARC score [0.842 (95% CI 0.754–0.93)], MELD [0.837 (95% CI 0.733–0.94)] score and SURFASA score [0.795 (95% CI 0.678–0.911)] were as accurate as ∆MELD at 2 weeks [0.770 (95% CI 0.687–0.845), p = 0.526] and better than ∆MELD at 3 days [0.541 (95% CI 0.395, 0.687), p < 0.001] to predict non-response. Combination of AARC score > 6, MELD score > 24 with SURFASA score ≥ − 1.2, could identify non-responders at day 3 (concomitant— 75% vs either − 42%, p < 0.001). Conclusion Baseline AARC score, MELD score, and the dynamic SURFASA score on day 3 can accurately identify early non-response to steroids in AIH-ACLF.